Latest Corporate News
IndiGo Airline Faces Chaos with Over 4,000 Flight Cancellations
India's largest airline, IndiGo, canceled over 4,000 flights starting December 2 due to crew shortages and scheduling issues, stranding thousands of passengers. Airports were overwhelmed with long queues and passengers sleeping in terminals, prompting regulatory scrutiny despite government exemptions.
The crisis highlights aviation sector vulnerabilities from staffing shortages and regulatory changes.
Kimberly-Clark Acquires Kenvue for $40 Billion Amid Controversy
Kimberly-Clark announced a $40 billion acquisition of Kenvue, the Tylenol maker facing weak sales, lawsuits, and White House criticism over autism claims linked to its painkiller. The deal has puzzled investors given Kenvue's challenges but aims to reshape consumer health.
It stands out as one of 2025's largest healthcare M&A transactions.
Johnson & Johnson Completes Acquisition of Intra-Cellular Therapies
Johnson & Johnson finalized its purchase of Intra-Cellular Therapies, integrating it as a business unit within J&J Innovative Medicine to bolster neuroscience leadership. The acquisition strengthens J&J's position in the evolving biotech landscape.
This is among 2025's notable life science deals.
Novartis to Buy Avidity Biosciences for $12 Billion
Swiss drugmaker Novartis agreed to acquire U.S. biotech Avidity Biosciences for $12 billion in cash to enhance its rare muscle disorder treatments portfolio. The deal underscores rapid industry evolution in rare diseases.
It highlights 2025's momentum in biotech M&A.
Merck Completes Acquisition of Verona Pharma
Merck announced the completion of its acquisition of Verona Pharma, making it a wholly-owned subsidiary focused on respiratory care innovations. Verona Pharma's ADS will no longer trade on Nasdaq.
This bolsters Merck's pipeline in key therapeutic areas.
M&A Activity Surges in Q3 with Record 14,720 Deals
Global M&A deals hit a year-to-date high of 14,720 in Q3 2025, with average premiums rising sharply from 15.5% to 63.25%. Quarterly counts exceeded 2024 levels, driven by megadeals like Norfolk Southern-Union Pacific at $88.4 billion.
Pending Q4 deals include Paramount's $103.6 billion bid for Warner Bros Discovery.
Google's $32 Billion Wiz Acquisition Tops Tech M&A
Google announced the largest tech buyout of 2025 with its $32 billion acquisition of cybersecurity startup Wiz, though the deal remains pending. Tech M&A value hit $543 billion this year, the highest since 2021.
VC-backed startup deals rebounded to $174.5 billion.
FullBeauty Brands Merges with Destination XL Group
FullBeauty Brands agreed to a merger of equals with Destination XL Group, with FullBeauty shareholders owning 55% of the combined public entity under DXLG ticker. A $92 million subscription will support the deal, expected to close in H1 2026.
Boards unanimously approved the transaction.
Cinven, KKR, Providence Sell MasOrange Stake for €4.25 Billion
Cinven, KKR, and Providence completed the sale of their stake in Spanish telecom operator MasOrange for €4.25 billion, marking a successful exit. The deal, advised by major banks like Goldman Sachs, is set to close in H1 2026 pending approvals.
It highlights robust telecom M&A activity.
PNC Receives Regulatory Approvals for FirstBank Acquisition
PNC Financial secured regulatory nods to acquire FirstBank, expanding its coast-to-coast franchise, with closure expected around January 5, 2026. CEO William Demchak emphasized bringing PNC's capabilities to more customers.
This strengthens PNC's community presence.
Crescent Energy Stockholders Approve Merger with Vital Energy
Crescent Energy shareholders overwhelmingly approved its merger with Vital Energy, announced on December 12, 2025. The energy sector deal advances consolidation in the industry.
It positions the combined entity for growth.
Sanofi Completes Acquisition of Blueprint Medicines
Sanofi finalized its purchase of Blueprint Medicines, adding expertise in systemic mastocytosis and KIT-driven diseases to its portfolio. The deal includes a commercialized medicine and promising pipeline.
It exemplifies 2025's healthcare M&A surge.